HRP20160168T1 - Kristalne forme makrolida i njihova uporaba - Google Patents

Kristalne forme makrolida i njihova uporaba Download PDF

Info

Publication number
HRP20160168T1
HRP20160168T1 HRP20160168T HRP20160168T HRP20160168T1 HR P20160168 T1 HRP20160168 T1 HR P20160168T1 HR P20160168 T HRP20160168 T HR P20160168T HR P20160168 T HRP20160168 T HR P20160168T HR P20160168 T1 HRP20160168 T1 HR P20160168T1
Authority
HR
Croatia
Prior art keywords
cem
solution
water
peaks
radiation
Prior art date
Application number
HRP20160168T
Other languages
English (en)
Croatian (hr)
Inventor
David E Pereira
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160168(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of HRP20160168T1 publication Critical patent/HRP20160168T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20160168T 2010-03-22 2011-03-22 Kristalne forme makrolida i njihova uporaba HRP20160168T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
EP11760068.4A EP2550286B1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Publications (1)

Publication Number Publication Date
HRP20160168T1 true HRP20160168T1 (hr) 2016-03-25

Family

ID=44673574

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160168T HRP20160168T1 (hr) 2010-03-22 2011-03-22 Kristalne forme makrolida i njihova uporaba

Country Status (19)

Country Link
US (4) US8975386B2 (enExample)
EP (2) EP2550286B1 (enExample)
JP (4) JP5711352B2 (enExample)
KR (2) KR102006200B1 (enExample)
CN (2) CN103080122A (enExample)
AU (2) AU2011232627B2 (enExample)
BR (1) BR112012023950A2 (enExample)
CA (1) CA2793884C (enExample)
DK (1) DK2550286T3 (enExample)
ES (1) ES2564097T3 (enExample)
HR (1) HRP20160168T1 (enExample)
IL (1) IL222018B (enExample)
MX (1) MX361413B (enExample)
MY (1) MY162411A (enExample)
NZ (1) NZ602544A (enExample)
PL (1) PL2550286T3 (enExample)
RU (1) RU2650883C2 (enExample)
SI (1) SI2550286T1 (enExample)
WO (1) WO2011119604A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080391A2 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
US8796232B2 (en) 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN108310000A (zh) 2009-09-10 2018-07-24 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
EP2550286B1 (en) * 2010-03-22 2015-12-09 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
RU2658050C2 (ru) 2012-03-27 2018-06-19 Семпра Фармасьютикалз, Инк. Парентеральные составы для введения макролидных антибиотиков
CN105163785A (zh) 2013-03-14 2015-12-16 森普拉制药公司 用于治疗呼吸道疾病的方法及其制剂
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
KR102528984B1 (ko) 2013-04-04 2023-05-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 매크롤라이드 그리고 그의 제조방법 및 용도
RU2017104163A (ru) * 2014-08-05 2018-09-06 Семпра Фармасьютикалз, Инк. Порошкообразные составы пероральных суспензий антибактериальных агентов
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
CA2963815A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CN107530365A (zh) 2015-03-25 2018-01-02 哈佛大学的校长及成员们 具有修饰的脱氧糖胺糖的大环内酯及其用途
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
TW201811811A (zh) * 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法
CA3163337A1 (en) * 2019-12-02 2021-06-10 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
SK285533B6 (sk) 1996-09-04 2007-03-01 Abbott Laboratories 6-O-substituované ketolidy s antibakteriálnou aktivitou, farmaceutická kompozícia s ich obsahom, ich použitie a spôsob ich prípravy
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
CN1259135A (zh) 1997-06-11 2000-07-05 辉瑞产品公司 9－肟红霉素衍生物
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
WO2000034297A1 (en) 1998-12-10 2000-06-15 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
ES2212655T3 (es) 1999-01-27 2004-07-16 Pfizer Products Inc. Antibioticos de cetolidos.
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
EP1171447A2 (en) 1999-04-16 2002-01-16 Ortho-McNeil Pharmaceutical, Inc. Ketolide antibacterials
EP1171446B1 (en) 1999-04-16 2006-09-20 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
EP1469008B1 (en) * 2000-03-15 2006-08-30 Hanmi Pharm. Co., Ltd. Method of preparing a non-pharmaceutical grade clarithromycin
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
JP2004534763A (ja) 2001-05-18 2004-11-18 カイロン コーポレイション アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物
US6756359B2 (en) 2001-07-03 2004-06-29 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
BR0307898A (pt) 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
CA2487424C (en) 2002-05-30 2011-01-04 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
WO2004080391A2 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
EP1618120A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
ES2294733T3 (es) 2004-04-28 2008-04-01 Alembic Limited Proceso para la preparacion de telitromicina.
WO2006080954A1 (en) 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
DE602005019786D1 (de) * 2004-12-21 2010-04-15 Pfizer Prod Inc Makrolide
DE602006016231D1 (de) 2005-01-14 2010-09-30 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
US20070167382A1 (en) * 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
EP2220104A1 (en) 2007-10-25 2010-08-25 Sandoz AG Process for the production of telithromycin
US8796232B2 (en) * 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
EP2550286B1 (en) 2010-03-22 2015-12-09 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor

Also Published As

Publication number Publication date
US8759500B2 (en) 2014-06-24
WO2011119604A1 (en) 2011-09-29
JP5711352B2 (ja) 2015-04-30
CN103080122A (zh) 2013-05-01
JP2020002168A (ja) 2020-01-09
DK2550286T3 (en) 2016-02-29
KR102006200B1 (ko) 2019-08-01
EP2550286A4 (en) 2013-10-02
MX2012010895A (es) 2013-02-15
AU2016203986B2 (en) 2016-10-06
JP2015063536A (ja) 2015-04-09
EP3009442B1 (en) 2019-06-19
JP2017081953A (ja) 2017-05-18
PL2550286T3 (pl) 2016-07-29
EP2550286A1 (en) 2013-01-30
KR20130056226A (ko) 2013-05-29
US8975386B2 (en) 2015-03-10
MX361413B (es) 2018-12-05
HK1177937A1 (en) 2013-08-30
CA2793884C (en) 2019-09-10
CN108570083A (zh) 2018-09-25
IL222018B (en) 2019-05-30
CA2793884A1 (en) 2011-09-29
AU2011232627A1 (en) 2012-10-18
MY162411A (en) 2017-06-15
RU2650883C2 (ru) 2018-04-18
EP3009442A1 (en) 2016-04-20
ES2564097T3 (es) 2016-03-17
JP2013522367A (ja) 2013-06-13
AU2016203986A1 (en) 2016-06-30
AU2011232627B2 (en) 2016-03-17
BR112012023950A2 (pt) 2016-07-05
SI2550286T1 (sl) 2016-04-29
EP2550286B1 (en) 2015-12-09
NZ602544A (en) 2014-11-28
RU2012144614A (ru) 2014-04-27
US20190040096A1 (en) 2019-02-07
US20130018008A1 (en) 2013-01-17
JP6121387B2 (ja) 2017-04-26
US20160244472A1 (en) 2016-08-25
KR20180101643A (ko) 2018-09-12
US20130252915A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
HRP20160168T1 (hr) Kristalne forme makrolida i njihova uporaba
HRP20201275T1 (hr) Kristalni oblik derivata benzimidazola i postupak njegove proizvodnje
WO2022222994A1 (zh) 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
HRP20160208T4 (hr) Polimorfi dasatiniba i postupak za njihovu pripremu
HRP20201644T1 (hr) Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba
RU2015137928A (ru) Полиморфные и псевдоплиморфные формы фармацевтического соединения
CN102746258B (zh) 卡巴他赛的结晶形式及其制备方法
HRP20210507T1 (hr) Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku
JP2014524442A5 (enExample)
RU2018145948A (ru) Кристалл пирролопиримидина для получения jak-ингибитора
HRP20170187T1 (hr) Polimorfni oblici 2-(5-brom-4-(4-ciklopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio) octene kiseline i njihova upotreba
HRP20150584T1 (hr) Soli i polimorfi tetraciklinskog spoja
RU2012131911A (ru) Композиция ребаудиозида а и способ очистки ребаудиозида а
CN102838571B (zh) 含γ-亚基丁烯内酯穿心莲内酯衍生物、其合成方法和用途
RU2014139702A (ru) Способ получения триглицеридов среднецепочечных жирных кислот
HRP20130026T1 (hr) Kristalni oblik posakonazola
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
RU2015100280A (ru) Многокомпонентные кристаллы, содержащие дазатиниб и определенные сокристаллобразователи
JP2022060192A5 (enExample)
ME02309B (me) Agomelatin hidrobromid hidrat i njegova priprema
HRP20180428T1 (hr) Antibakterijski derivati tilozina i postupci njihovog dobivanja
RU2019106531A (ru) Кристалл соли производного хиназолина
ITMI20131307A1 (it) Processo per la preparazione di refaximina k
HRP20191522T1 (hr) Kristalinični oblici s-acetil-glutationa, njihove priprave i upotrebe u farmaceutskim i nutraceutskim formulacijama
CN103880904B (zh) 非达霉素晶型i及其制备方法